Skip to Main Content

Hello, everyone, and welcome to the middle of the week. Congratulations on making it this far and remember there are only a few more days until the weekend arrives. So keep plugging away. After all, what are the alternatives? While you ponder the possibilities, we invite you to join us for a delightful cup of stimulation. Remember that no prescription is required. Meanwhile, here is the latest menu of tidbits to help you on your way. Have a wonderful day and please do stay in touch …

Sanofi and Regeneron Pharmaceuticals filed a lawsuit seeking to preempt a possible patent challenge from Amgen over their forthcoming Dupixent drug for atopic dermatitis. The companies want a court order declaring the drug, which the Food and Drug Administration is expected to be approve shortly, does not infringe on an Amgen patent for a failed asthma treatment. The suit comes two months after another court blocked Sanofi and Regeneron from selling their Praluent cholesterol drug after losing a patent infringement case to Amgen. But Praulent remains on the market during an appeal.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Comments are closed.